BioAge Labs Inc. – Material Contracts Watch

from 10-K 66 pages Purpose. the Purpose of This Plan Is to Provide Incentives to Attract, Retain and Motivate Eligible Persons Whose Present and Potential Contributions Are Important to the Success of the Company, and Any Parents, Subsidiaries and Affiliates That Exist Now or in the Future, by Offering Them an Opportunity to Participate in the Company’s Future Performance Through the Grant of Awards. Capitalized Terms Not Defined Elsewhere in the Text Are Defined in Section 28. 2. Shares Subject to the Plan. 2.1

from 10-Q 90 pages Office/Laboratory Lease Between Es East, LLC (Landlord) and BioAge Labs, Inc. (Tenant) 5885 Hollis Street Emeryville, California

from 8-K 53 pages Share Purchase Agreement

from S-1/A 3 pages This Employment Letter Sets Forth the Terms Confirms Your Continued Employment as Chief Medical Officer of BioAge Labs, Inc., a Delaware Corporation (The “Company” or “Bioage”). You Will Continue to Report to the Chief Executive Officer. This Employment Letter Amends and Restates the Employment Letter Entered Into Between You and Bioage, Dated on or About April 29, 2020 and the Executive Severance and Change in Control Agreement Dated on or About January 1, 2023 (The “Prior Agreements”). This Letter Is Effective as of the Date on Which the Registration Statement Covering the Initial Public Offering of the Shares of Common Stock of the Company Is Declared Effective by the U.S. Securities and Exchange Commission (The “Ipo Effective Date”). 1. Compensation

from S-1/A 3 pages This Employment Letter Sets Forth the Terms Confirms Your Continued Employment as Chief Operating Officer of BioAge Labs, Inc., a Delaware Corporation (The “Company” or “Bioage”). You Will Continue to Report to the Chief Executive Officer. This Employment Letter Amends and Restates the Employment Letter Entered Into Between You and Bioage, Dated on or About November 28, 2017 and the Executive Severance and Change in Control Agreement, Dated on or About January 1, 2023 (The “Prior Agreements”). This Letter Is Effective as of the Date on Which the Registration Statement Covering the Initial Public Offering of the Shares of Common Stock of the Company Is Declared Effective by the U.S. Securities and Exchange Commission (The “Ipo Effective Date”). 1. Compensation

from S-1/A 3 pages This Employment Letter Sets Forth the Terms Confirms Your Continued Employment as Chief Executive Officer of BioAge Labs, Inc., a Delaware Corporation (The “Company” or “Bioage”). You Will Continue to Report to the Board of Directors of the Company (The “Board”) and Will Remain a Member of the Board. This Employment Letter Amends and Restates Any Prior Employment Letter Entered Into Between You and Bioage, Including the Executive Severance and Change in Control Agreement Dated on or About January 1, 2023 (The “Prior Agreement”). This Letter Is Effective as of the Date on Which the Registration Statement Covering the Initial Public Offering of the Shares of Common Stock of the Company Is Declared Effective by the U.S. Securities and Exchange Commission (The “Ipo Effective Date”). 1. Compensation

from S-1/A 10 pages Executive Severance and Change in Control Plan

from S-1/A 18 pages BioAge Labs, Inc. 2024 Employee Stock Purchase Plan

from S-1/A 72 pages BioAge Labs, Inc. 2024 Equity Incentive Plan

from S-1/A 14 pages Form of Indemnity Agreement

from S-1 24 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That BioAge Labs, Inc. Treats as Private or Confidential. Material Transfer Agreement

from S-1 61 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That BioAge Labs, Inc. Treats as Private or Confidential. Exclusive License Agreement by and Between Amgen Inc. and BioAge Labs, Inc. Dated as of April 5, 2021

from S-1 52 pages Air Commercial Real Estate Association Standard Industrial/Commercial Multi-Tenant Lease - Gross

from S-1 72 pages BioAge Labs, Inc. 2015 Equity Incentive Plan as Adopted on August 14, 2015 as Amended on June 2, 2017 as Amended and Restated on October 16, 2017 as Amended on December 7, 2018 as Amended on October 24, 2020 as Amended on December 16, 2021 as Amended on March 29, 2023 as Amended on January 31, 2024

from DRS/A 61 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That BioAge Labs, Inc. Treats as Private or Confidential. Exclusive License Agreement by and Between Amgen Inc. and BioAge Labs, Inc. Dated as of April 5, 2021

from DRS 24 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That BioAge Labs, Inc. Treats as Private or Confidential. Material Transfer Agreement

from DRS 60 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Is the Type That BioAge Labs, Inc. Treats as Private or Confidential. Exclusive License Agreement by and Between Amgen Inc. and BioAge Labs, Inc. Dated as of April 5, 2021

from DRS 52 pages Air Commercial Real Estate Association Standard Industrial/Commercial Multi-Tenant Lease - Gross

from DRS 72 pages BioAge Labs, Inc. 2015 Equity Incentive Plan as Adopted on August 14, 2015 as Amended on June 2, 2017 as Amended and Restated on October 16, 2017 as Amended on December 7, 2018 as Amended on October 24, 2020 as Amended on December 16, 2021 as Amended on March 29, 2023 as Amended on January 31, 2024